The Children's Hospital Corporation (Boston Children's Hospital) received a Project Grant award of $254,610 from the National Institute of Neurological Disorders and Stroke (part of the National Institutes of Health) under the Drug Use and Addiction Research Programs (CFDA 93.279). This funding will support research to validate drugs that block neuroimmune communication and macrophage-targeting drugs as novel, non-hormonal, and non-opioid approaches for treating endometriosis-associated pain. The project aims to identify the inflammatory mediators and signaling pathways activated in macrophages upon CGRP stimulation, as well as determine the mechanisms by which maresin-1, a pro-resolving lipid mediator, resolves pain and inflammation in endometriosis. The research will also investigate how neuroimmune communication drives omental colonization by macrophages and pinpoint the nociceptor-responsive macrophage population responsible for endometriosis pain and lesion formation. The award period is from July 15, 2024 to June 30, 2026.
Generated 1/28/25, 7:41 AM